Last reviewed · How we verify
DTacP-IPV/Hib
DTacP-IPV/Hib is a Combination vaccine Biologic drug developed by Changchun BCHT Biotechnology Co.. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.
DTacP-IPV/Hib is a combination vaccine that provides immunization against diphtheria, tetanus, acellular pertussis, poliomyelitis, and Haemophilus influenzae type b through inactivated antigens and toxoids.
DTacP-IPV/Hib is a combination vaccine that provides immunization against diphtheria, tetanus, acellular pertussis, poliomyelitis, and Haemophilus influenzae type b through inactivated antigens and toxoids. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.
At a glance
| Generic name | DTacP-IPV/Hib |
|---|---|
| Sponsor | Changchun BCHT Biotechnology Co. |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | Phase 3 |
Mechanism of action
This pentavalent vaccine contains diphtheria and tetanus toxoids, acellular pertussis antigens, inactivated poliovirus antigens, and Haemophilus influenzae type b conjugate antigen. Upon administration, these antigens stimulate the immune system to produce antibodies and cellular immunity against these five pathogens, providing protection against the corresponding infectious diseases.
Approved indications
- Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children
Common side effects
- Injection site reactions (pain, redness, swelling)
- Fever
- Irritability
- Drowsiness
Key clinical trials
- Adsorption of Cell-free Diphtheria and Tetanus (Three-component) Combined With Vaccine Phase III Clinical Trial (PHASE3)
- Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine (PHASE1)
- Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™ (PHASE3)
- Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China (PHASE4)
- Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infants (PHASE3)
- Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months (PHASE3)
- Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. (PHASE3)
- Immunogenicity and Safety of Pentaxim™ in an Indian Population (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTacP-IPV/Hib CI brief — competitive landscape report
- DTacP-IPV/Hib updates RSS · CI watch RSS
- Changchun BCHT Biotechnology Co. portfolio CI
Frequently asked questions about DTacP-IPV/Hib
What is DTacP-IPV/Hib?
How does DTacP-IPV/Hib work?
What is DTacP-IPV/Hib used for?
Who makes DTacP-IPV/Hib?
What drug class is DTacP-IPV/Hib in?
What development phase is DTacP-IPV/Hib in?
What are the side effects of DTacP-IPV/Hib?
Related
- Drug class: All Combination vaccine drugs
- Manufacturer: Changchun BCHT Biotechnology Co. — full pipeline
- Therapeutic area: All drugs in Immunology / Infectious Disease Prevention
- Indication: Drugs for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children
- Compare: DTacP-IPV/Hib vs similar drugs
- Pricing: DTacP-IPV/Hib cost, discount & access